IDH2 and colorectal carcinoma: Moreover, some clinical trials of CB-839 alone or in combination with anticancer drugs are ongoing, such as with capecitabine for PIK3CA mutant CRC (NCT02861300), with temozolomide for IDH-mediated diffuse astrocytoma (NCT03528642), with carfilzomib and dexamethasone for recurrent or refractory multiple myeloma (NCT03798678), and with chemoradiation for advanced cervical cancer (NCT05521997).